Citizens JMP analyst Jason Butler raised the firm’s price target on Prothena (PRTA) to $19 from $11 and keeps an Outperform rating on the shares. Prothena has potential to receive up to $105M in clinical milestone payments by year end 2026 associated with the advancement of coramitug for ATTR amyloidosis and PRX019 for neurodegenerative diseases, the analyst tells investors in a research note. These programs demonstrate the success of Prothena’s discovery engine, further supported by the earlier-stage pipeline programs and the company’s emerging preclinical pipeline, the firm says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena price target raised to $8 from $4 at BofA
- Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials
- Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
- Prothena Shareholders Approve Capital Reduction Proposal
- Prothena announces poster presentation on TDP-43 CYTOPE program